JournalArta
Thursday, November 19, 2026 · JakartaS&P 7,245.47 ▼1.07%USD/IDR 18,280 ▲0.29%
JournalArta
Global Edition
beyond headlines
Advertisement

China Drug Deals Raise Supply Concerns, US Panel Warns

A US congressional commission says pharmaceutical licensing deals with Chinese biotechnology companies could increase American dependence on Chinese innovation. Its analysis of 57 deals comes as both governments consider restrictions affecting biotechnology trade and investment.

By Alistair Sterling
November 19, 20262 min read
China Drug Deals Raise Supply Concerns, US Panel Warns
China Drug Deals Raise Supply Concerns, US Panel Warns

The National Security Commission on Emerging Biotechnology warned in a new analysis that China's drug supply chain ambitions could threaten US access to future treatments.

The commission examined 57 pharmaceutical deals from the beginning of 2023 through the month before its analysis. It found that Western drugmakers increasingly license treatments from Chinese companies, directing US capital toward China's pharmaceutical industry.

The warning comes as both countries consider restrictions affecting biotechnology. China proposed export restrictions on certain technologies, including cell and gene therapy platforms. Such therapies aim to treat disease using cells or genetic material.

Advertisement

Deals move earlier in development

In a typical licensing deal, a Chinese biotechnology company sells a multinational drugmaker the rights to develop or commercialize a treatment.

Western companies use the arrangements to shift some of the burden of drug discovery and verify early results. AstraZeneca, Bristol Myers Squibb and Pfizer are among the drugmakers drawn by China's life sciences investment and the promise of faster trials and approvals.

The commission found that deals increasingly rely on preclinical data, collected before a treatment reaches human trials. Upfront payments are also arriving earlier in research and development.

That timing gives Chinese partners capital and expertise in developing and commercializing treatments, the commission said. Royalties and stakes in joint ventures can flow back to China, funding research and infrastructure and attracting talent.

Advertisement

Commission Executive Director Caitlin Frazer said the deals risk eroding US biotechnology research and development. She added: “This trend should be alarming for policymakers.”

Washington weighs investment restrictions

The Trump administration proposed new screening requirements for certain deals with Chinese life sciences companies, as well as outright prohibitions for others.

The administration cited risks that investments could support biological weapons or surveillance technologies, or make US supply chains overly dependent on one country.

Under the proposal, cash-based deals involving royalties and payments tied to development milestones would remain permitted. Equity investments in Chinese firms would be prohibited, and certain joint ventures could also face restrictions, according to an analysis by Sidley.

Advertisement

Congress established the commission to examine the national security implications of emerging biotechnology. The panel called the proposed restrictions a prudent step, while urging policymakers to strengthen US innovation.

Brookings Institution senior fellow Marta Wosińska has noted that drug shortages can delay treatment for seizures, infections or severe pain.

In an earlier report to Congress, the commission described a hypothetical scenario in which Beijing withheld a breakthrough treatment from American patients during a conflict in Taiwan.

Advertisement
Take the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Advertisement
Most Read
  1. 1Brent Crude Slides 4.05% as Rising US Stockpiles Weigh on Oil
  2. 2UnitedHealth Shares Fall 10.2% Amid Medicare Audit Proposal
  3. 3PNB Shares Rally 5% as Bank Repeats Loan Growth Target
  4. 4Usman Khawaja Cancels Interview After Bancroft Claims
  5. 5Lainey Wilson and Devlin Hodges Married in Tennessee Cave
Advertisement
Don't Miss

Latest News

All stories →
  1. WorldUN Court Finds Myanmar Committed Rohingya GenocideNov 19
  2. Markets · StocksSouth32 Share Price on Thursday: Tumbles 5.87%, Near a 3-Month LowNov 19
  3. Markets · StocksInsurance Australia Share Price Latest: Little Changed on Thursday, Up 1.3% in a MonthNov 19
  4. World · United StatesWhite House Takes Pool Phones Before Trump Leaves ChinaNov 19
  5. Advertisement
  6. Markets · StocksCommBank Share Price on Thursday: Rises 0.44%, Up 9.2% in a MonthNov 19
  7. Sport · More SportsCody Walker Lands Safely at Carlton After No. 3 BidNov 19
  8. Markets · StocksOrigin Energy Share Price Falls 1.11% on Thursday, Up 2.7% in Five SessionsNov 19
  9. World · EuropeTurkey Urges EU to Include Its Cars in Subsidy PlanNov 19